TY - JOUR
KW - drug efficacy
KW - cost-effectiveness
KW - adjunctive personalized psychosocial intervention treatment-resistant maintenance
KW - opioid agonist therapy
KW - Pragmatics
KW - Randomized Controlled Trials
KW - Clinical Trial
KW - Empirical Study
KW - Interview
KW - Quantitative Study
KW - Human
KW - Male
KW - Female
KW - Adulthood (18 yrs & older)
KW - Intervention
KW - Costs and Cost Analysis
KW - Drug Therapy
KW - Opiates
KW - Psychosocial Rehabilitation
KW - Adjunctive Treatment
KW - Treatment Resistant Disorders
KW - cocaine
KW - Maintenance Therapy
KW - Treatment Effectiveness Evaluation
KW - Precision Medicine
KW - United Kingdom
KW - article
KW - 3383:Drug & Alcohol Rehabilitation
KW - Quality-Adjusted Life Years
KW - Analgesics, Opioid
KW - Humans
KW - Middle Aged
KW - Treatment Outcome
KW - Combined Modality Therapy
KW - cognitive behavioral therapy
KW - Cost-Benefit Analysis
KW - Intention to Treat Analysis
KW - opioid-related disorders
KW - Adult
KW - Opiate Substitution Treatment
AU - John Marsden
AU - Garry Stillwell
AU - Kirsty James
AU - James Shearer
AU - Sarah Byford
AU - Jennifer Hellier
AU - Michael Kelleher
AU - Joanna Kelly
AU - Caroline Murphy
AU - Luke Mitcheson
A1 - 
AD - Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom john.marsden@kcl.ac.uk; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom ; King’s Health Economics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom ; Lambeth Addictions, South London and Maudsley NHS Mental Health Foundation Trust, London, United Kingdom ; King’s Clinical Trials Unit at King’s Health Partne, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom ; King's Clinical Trials Unit at King's Health Partners, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom ; Marsden, John,DeCrespigny Park, Denmark Hill,London,United Kingdom,SE5 8AF,Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London,john.marsden@kcl.ac.uk
BT - The Lancet Psychiatry
C5 - Education & Workforce; Financing & Sustainability; Opioids & Substance Use
CP - 5
DO - 10.1016/S2215-0366(19)30097-5
IS - 5
JF - The Lancet Psychiatry
LA - English
M1 - Journal Article
PB - Elsevier Science David Collingdre
PY - 2019
SN - 2215-0366, 2215-0366
SP - 391
EP - 402
EP - 
T1 - Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: A pragmatic, open-label, randomised controlled trial
T2 - The Lancet Psychiatry
TI - Efficacy and cost-effectiveness of an adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: A pragmatic, open-label, randomised controlled trial
U1 - Education & Workforce; Financing & Sustainability; Opioids & Substance Use
U3 - 10.1016/S2215-0366(19)30097-5
UR - https://www.proquest.com/scholarly-journals/efficacy-cost-effectiveness-adjunctive/docview/2229358968/se-2?accountid=28100
VL - 6
VO - 2215-0366, 2215-0366
Y1 - 2019
Y2 - 05
ER -